Abbott (ABT) Announces Publication of Positive Infant Formula with 2'-FL Human Milk Oligosaccharide+ Data
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Good nutrition helps build the foundation for a child's ability to learn, grow and thrive. For babies, the best nutrition is breast milk – there's nothing in the world like it – in part due to special prebiotics called human milk oligosaccharides (HMOs). HMOs, found naturally in breast milk, feed good bacteria in the gut. Researchers believe they may be one of the main reasons breastfeeding provides immune health benefits. Now, a new study offers news about HMOs for parents who need or choose to use infant formula.
The study, published today in the Journal of Nutrition, shows that babies fed infant formula with a structurally identical version of 2'-fucosyllactose (2'-FL), the most abundant HMO found in most human milk, had an immune response more like breastfed babies.1
Immune Support For Formula-Fed Babies The prospective, randomized, double-blind clinical study looked at the immune response of 200 babies divided into feeding groups – exclusively breastfed, formula-fed without 2'-FL HMO and formula-fed with 2'-FL HMO. After six weeks, results showed that when comparing the breastfed group to the group fed formula without 2'-FL HMO, the levels of five immune markers were statistically different. Levels of these same markers, however, were nearly identical between the breastfed group and the group fed formula with 2'-FL HMO.1
"The first year of life is an important window for immune system development," said Edward Barrett, Ph.D., study author and Director of Translational Research at Lovelace Biomedical, part of the Lovelace Respiratory Research Institute. "These data are compelling for doctors and parents alike because we were able to show that the formula with 2'-FL HMO narrowed the gap between breast milk and formula in ways never seen before. We tested a number of immune markers, and found that specific signals of immune responses were the same in the breastfed and 2'-FL-formula fed babies."
Excluding water, HMOs are the third most abundant ingredient in breast milk after fat and carbohydrates. There are hundreds of HMOs in human milk, and they are more than 100 times more abundant in breast milk than cow's milk.2 Like other prebiotics, HMOs support gut health, where 70 percent of the immune system exists.3 But, studies show that 2'-FL HMO also circulates in the bloodstream throughout the body.4
"Nothing can replace breast milk. But for those moms who need or choose to use formula, we are committed to providing the most scientifically advanced nutrition," said Rachael Buck, Ph.D., associate research fellow at Abbott and study author. "This latest research has led us to our biggest scientific breakthrough in infant formula in nearly a decade – the ability to nourish formula-fed babies with 2'-FL HMO. While it doesn't mean babies won't experience the normal illnesses that come with childhood, these data clearly show that formula with 2'-FL HMO can help strengthen babies' immune systems to be more like breastfed babies."
The formula used in the study is available at major U.S. retailers and the Abbott store as Similac® Pro-Advance™ and Similac Pro-Sensitive™, both non-GMO. Abbott is the first company to add an HMO to infant formula.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Digital Ally (DGLY) Refutes TASER's Attack on ‘292 Patent; Says Nothing New Here
- Franklin Street Properties (FSP) Acquires Denver-Located Dominion Towers
- MyoKardia (MYOK) Receives $25M Milestone Related to MYK-491 Development (SNY)
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!